Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health
Cannabiscientia SA, Lugano, Switzerland
Depar High Performance Research Group in Physiopathology and Pharmacology of the Digestive System NeuGut-URJC, Department of Basic Health Sciences, Faculty of Health Sciences, Universidad Rey Juan Carlos (URJC), Madrid, Spain
R & D & I Unit Associated with the Institute of Medicinal Chemistry (IQM), Spanish National Research-Council (CSIC), Madrid, Spain
Spanish Pain Society Working Groups on Basic Sciences in Pain and Analgesia and on Cannabinoids, Madrid, Spain
Abstract
The maintenance of homeostasis in the gastrointestinal (GI) tract is ensured by the presence of the endocannabinoid system (ECS), which regulates important physiological activities, such as motility, permeability, fluid secretion, immunity, and visceral pain sensation. Beside its direct effects on the GI system, the ECS in the central nervous system indirectly regulates GI functions, such as food intake and energy balance. Mounting evidence suggests that the ECS may play an important role in modulating central neurotransmission which affects GI functioning. It has also been found that the interaction between the ECS and microbiota affects brain and gut activity in a bidirectional manner, and a number of studies demonstrate that there is a strong relationship between GI dysfunctions and mood disorders. Thus, microbiota can regulate the tone of the ECS. Conversely, changes in intestinal ECS tone may influence microbiota composition. In this mini-review, we propose the concept of neuro-gastro-cannabinology as a novel and alternative paradigm for studying and treating GI disorders that affect mood, as well as mood disorders that imbalance GI physiology. This concept suggests the use of prebiotics or probiotics for improving the tone of the ECS, as well as the use of phytocannabinoids or endocannabinoid-like molecules, such as palmitoylethanolamide, to restore the normal intestinal microbiota. This approach may be effective in ameliorating the negative effects of GI dysfunctions on mood and/or the effects of mood disorders on digestive health.
Untitled section
Keywords: Cannabinoid treatment, Gut-brain axis, Mood disorders, Gastroinstestinal disorders, Probiotics, Endocannabinoid system
Article notes
Untitled section
Received 2023 Apr 28; Accepted 2023 Aug 30; Collection date 2023 Jan-Dec.
Introduction
Homeostasis is derived from the ancient Greek words ὅμοιος and στάσις, meaning “staying the same”. As a biological concept, it refers to the attitude of living organisms toward maintaining a steady balance when their conditions are optimal [1]. This can be regarded as a natural adaptive process of preservation of nearly constant conditions in the internal environment. As with other areas of the human body, the maintenance of intestinal homeostasis is fundamentally relevant to health. It is crucial that the digestive and defensive functions of the gut are integrated and balanced to protect the body against insults caused, i.e., by indigestion, pathogens, and toxins. Intestinal equilibrium is maintained by a variety of pathways and cells, including immune, epithelial, neuronal, glial, and endocrine cells [2]. Microbiota-gut-brain interactions also play an important role in this process [3]. It is in this context that the endocannabinoid system (ECS) emerges as a key modulator of intestinal homeostasis. Several intestinal physiological processes are regulated by the ECS, a network of lipid mediators that have been found ubiquitously throughout the entire gastrointestinal (GI) system. The presence of the ECS in the GI tract has been extensively described elsewhere [4, 5]. Briefly, the gut is home to both cannabinoid (CB) receptors, CB1 and CB2, their endogenous ligands, termed endocannabinoids, such as anandamide and 2-arachidonoylglicerol (2-AG), and the enzymes responsible for their biosynthesis and degradation. Several non-typical cannabinoid members are also expressed, including the transient receptor potential (TRP) channels, such as TRPV1 and TRPM8, proliferator-activated receptors (PPARs), G protein-coupled receptors (GPRs), and endocannabinoid-like molecules, including palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) [4, 5]. In the human body, the endocannabinoid signaling pathways are involved in regulating a variety of biological and cognitive processes (such as appetite, pain sensation, and mood) and in mediating the pharmacological effects of cannabis [6–12]. The ECS in the GI tract regulates important physiological activities, such as intestinal motility, permeability, fluid secretion, immunity, and visceral pain sensation [12, 13]. Apart from the direct effects on the GI system, the ECS in the central nervous system (CNS) indirectly controls intestinal functions, such as food intake and energy balance [10, 14, 15]. It is now well established that the brain and gut communicate bidirectionally to control a variety of physiological processes, through the gut-brain axis. Evidence suggests that the ECS may play an important role in modulating central neurotransmission which affects GI functioning [3, 16–19]. It has also been found that the interaction between the ECS and microbiome affects brain and gut activity in a bidirectional manner [20–22]. The ECS plays a role in modulating both emotional and non-emotional behavior [23–26]. Signals originating from the ECS are known to influence the hypothalamic-pituitary-adrenocortical (HPA) axis, which is the mammals’ primary stress response system [27–29]. It has been demonstrated that dysbiosis and/or altered endocannabinoid tone contribute to mood changes and that mood disorders affect gut physiology [30–32]. Moreover, growing evidence suggests a role of the ECS in regulating the circadian sleep-wake cycle, and dysregulation of this circuit can lead to both mood and GI disorders [33–35]. The ECS is also involved, at least in part, in the induction of placebo effects, especially in placebo analgesia [36]. Bringing all this evidence together, we propose the concept of neuro-gastro-cannabinology as a novel and alternative paradigm for studying and treating GI disorders that affect mood, as well as mood disorders that imbalance GI physiology.
Role of the ECS in Mediating Gut and Brain Interactions
In both the peripheral nervous system and the CNS, the ECS plays a critical role in modulating and fine-tuning synaptic transmission. CB1 and, to a lesser extent, CB2 are located in nerve fibers throughout the gut, but their concentration is highest in the myenteric and submucosal plexi [37]. Importantly, CB receptors are believed to be localized only to excitatory nerves in the gut [38]. The endocannabinoids function as retrograde neurotransmitters since they are synthetized in the postsynaptic cell, then cross the synapse and activate CB receptors presynaptically [39]. Conversely, CB2 and, to a lesser extent, CB1 are mainly expressed in intestinal immune cells, where they are involved in modulating intestinal inflammation as well as abnormal motility, visceral sensitivity, and pain [40]. ECS activation induces an overall inhibitory effect on gut cells’ functions, particularly on cholinergic neurons. This inhibitory physiological mechanism may be exploited in pathological conditions, by enhancing or decreasing the ECS tone; indeed, the ECS affects motility, pain, secretion, and inflammation; moreover, the brain and the GI system are intimately connected. Accumulating evidence is suggestive of the ECS linking gut microbiota to CNS pathophysiology (shown in Fig. 1) [20, 41]. Besides helping to digest nutrients and protect against pathogenic bacteria, the gut microbiota has a significant impact on the activities of the CNS, particularly mood. There is a strong relationship between GI dysfunctions and mood disorders [42]; both functional and chronic inflammatory GI disorders, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), are often associated with affective ailments, such as depression, anxiety, panic, and post-traumatic stress disorder (PTSD) [43]. Conversely, mood disorders can lead to the development of GI diseases, such as functional dyspepsia and gastric ulcer [44, 45]. A possible link between gut and brain disorders may be represented by the crosstalk between the gut microbiota and the ECS. A study in 2007 reported that the commensal bacterium Lactobacillus acidophilus increased intestinal epithelial CB2 expression when administered orally to mice and rats [46]. Changes in gut microbiota also affect the levels of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), and CB1 mRNA [47, 48]. By treating mice with the commensal bacterium Akkermansia muciniphila, levels of endocannabinoids in the gut are increased, and the metabolic dysregulation caused by a high-fat diet can be reversed [49]. Also, in obese mice, CB1 antagonist SR141716A increases Akkermansia muciniphila levels and decreases Lachnospiraceae and Erysipelotrichaceae levels, which are implicated in gaining weight and induction of metabolic syndrome [50]. A common feature of GI diseases, such as IBS, IBD, and functional dyspepsia, is dysbiosis, a disturbance in gut microbial composition and function caused by both environmental and internal factors. Dysbiosis has been repeatedly associated with chronic GI disorders and metabolic disorders, such as IBD, obesity, diabetes mellitus, cancer, and cardiovascular diseases [51–53]. Furthermore, dysbiosis, as well as intestinal inflammation and loss of gut integrity, is also linked to mood disorders, such as anxiety and depression, as well as more severe psychiatric and neurologic conditions, such as schizophrenia, autism, or neurodegenerative diseases [54, 55]. Changes in microbiota composition induced by dysbiosis are correlated with hippocampal and gut alterations in some members of the ECS [48]. Interestingly, probiotic supplementation reduced gut inflammation and decreased depression-like behavior by normalizing gut microbiota and reversing biochemical and functional changes in the hippocampus [48]. Dysbiosis-induced changes in the ECS tone can also induce pain, which can be reverted with PEA supplements that restore the microbiota and endocannabinoid tone to normal [55]. Intriguingly, a significant increase in Akkermansia muciniphila, Eubacterium, and Enterobacteriaceae is observed following PEA administration, suggesting that PEA has anti-inflammatory properties as well as the ability to regulate gut dysbiosis [56]. Fecal microbiota transplantation from mildly stressed mice, a mouse model of depression, caused depression-like behavior in recipient mice [57]. There were significant molecular and behavioral alterations in the recipient mice associated with reduced serum lipid precursors for the production of ECS ligands, as well as a decrease in brain endocannabinoids levels, supporting the hypothesis that stress causes a lower endocannabinoid tone, where gut microbial composition imbalance might be a factor. Other studies have shown dramatic changes in the intestinal ECS in germ-free mice, including reduced gene expression of CB1, GPR55, and PPARα in the gut, and fecal transplants partially reversed these changes, suggesting that microbiota composition profoundly affects the intestinal endocannabinoid tone [58]. Human studies have shown that dysbiosis triggers gut-microbial alterations that contribute to anhedonia and amotivation via the ECS, especially through changes in PEA serum levels [59]. Taken these data together, it seems that the ECS is implied in the CNS consequences of gut dysbiosis. One explanation may be that commensal microorganisms affect ECS signaling by directly producing endocannabinoid-like molecules able to bind the receptors of the ECS [52]. Furthermore, as CB1 is expressed in vagal afferents that innervate various regions of the GI tract, the ECS may also modulate vagus nerve transmission, which is crucial for controlling food intake, hedonic feeding, visceral pain, aversion, and emotions by modulating the microbiota-gut-brain axis [47]. Studies using germ-free mice further confirm the relationship between the microbiota, ECS, and brain. As reported in a 2017 paper, the alterations in gut microbiota composition affect both brain and gut levels of endocannabinoids [60]. This study suggests that the endocannabinoid-like compound OEA, through its binding to GRP111 receptors, influences the secretion of the satiating hormone GLP-1, thus improving cognitive functions in patients with mood disorders [60]; therefore, microbiota have the potential to regulate the tone of the ECS. On the other hand, alterations in the intestinal ECS tone could also have an impact on the composition of the microbiota. An altered intestinal ECS modifies microbiota composition and may contribute to chronic abdominal pain, a common symptom of anxiety and depression, as well as GI disorders [56]. Intestinal permeability and metabolic endotoxemia are reduced by a CB1 antagonist, which also induces an imbalance in gut microbiota composition and a decrease in inflammation and macrophage levels in the adipose tissue of diet-induced obese mice. Conversely, a probiotic strain of Escherichia coli engineered to produce endocannabinoids can reduce adiposity in mice on a high-fat diet by suppressing food intake, improving insulin sensitivity, and reducing liver fibrosis [61]. Thus, by using engineered bacteria, it may be possible to manipulate gut ECS signaling to provide therapeutic benefits. Numerous studies have demonstrated the interaction between the gut microbiota and the HPA axis, indicating that stress-induced activation of this neuroendocrine system may be affected by the composition of the gut microbiota [62, 63]. There is also evidence suggesting that stress reduces the levels of endocannabinoids, especially 2-AG, which may lead to GI issues [64]. It is unclear whether stress-induced microbiota modification affects the ECS tone or if the effect of stress on the ECS changes microbiota composition. However, restoring normal microbiota or improving the ECS tone may be effective in counteracting the negative effects of stress on mood or digestive health.
Potential Interventions Targeting the ECS in GI and Mood-Related Disorders
A number of studies have described the use of prebiotics, probiotics, or both in treating anxiety and depression both in animal and human studies [47, 65–70]. Notably, in vagotomized mice, probiotic-related effects on neurochemical changes as well as on behavior were abolished, again suggesting a role of the vagus nerve in these beneficial reactions [65]. In light of these findings, our review suggests the modulation of the microbiota composition as a first-line treatment or an adjuvant to psychiatric intervention for anxiety and depression, using prebiotics or probiotics (shown in Fig. 2). Such treatments may be especially beneficial to patients who suffer from GI co-morbidities, such as IBS or dyspepsia [71]. Additionally, phytocannabinoids can also be used to improve the composition of the microbiota. The chronic treatment of obese rodents with tetrahydrocannabinol (THC) caused an altered microbiota with a higher Firmicutes:Bacteroidetes ratio, an increase in Akkermansia muciniphila abundance, and reduced obesity concurrently [72]. Capsaicin, a TRPV1 agonist, increased butyrate-producing Ruminococcaceae and Lachnospiraceae in obese rodents while decreasing LPS production [73]. Fecal microbiota transplant into germ-free mice revealed that capsaicin-induced obesity resistance was transferrable, demonstrating the importance of the microbiota [73]. Researchers examined the gut microbiome of mice treated with cannabidiol (CBD)-enriched cannabis extracts as well as the associated histomorphological and molecular changes in their gut mucosa [73]. There was a significant increase in Akkermansia muciniphila relative abundance; nevertheless, the colon tissue had increased levels of pro-inflammatory cytokines and chemokines, and gut integrity was decreased. As a result, questions have been raised about the potential long-term effects on the microbiome of therapeutic CBD application in humans. Interestingly, the mice used in this study were not pathological, so the situation may have differed if an induced pathological state, such as obesity or gut inflammation, had been present [74]. In addition to phytocannabinoids, endocannabinoid-like molecules, such as PEA and OEA, by restoring microbiota normal composition and counteracting central and peripheral neuroinflammatory responses, may be beneficial in improving both brain and gut health simultaneously (shown in Fig. 2) [56, 60, 75]. Furthermore, because mood disorders, such as depression, are preceded by patterns of poor appetite and skipping meals, improving the ECS tone (with prebiotics, probiotics, phytocannabinoids, endocannabinoids, endocannabinoids-like molecules, and compounds that modify the levels of endocannabinoids) may have a beneficial effect as it positively affects food intake and eating habits [15, 76, 77]. Mood and digestive disorders may be related to altered circadian rhythms, which can be disrupted by stress [33, 34]. Microbiota composition and abundance also follow circadian rhythms [35]; when stress-related alterations of the circadian rhythm occur because of the effects of the ECS on the sleep-wake cycle, restoring the microbiota’s normal composition and enanchiong the endocannabinoid tone with phytocannabinoids or compounds that enhance endocannabinoids activity may provide benefits (shown in Fig. 2).
Conclusion
ECS signaling and gut microbiota have reciprocal interactions, which, in turn, influence the organism response via the gut-brain axis and may contribute to the protection from stress-related diseases and mood alterations, as well as from GI disorders. This is consistent with the fact that the ECS facilitates the homeostatic state of the organism and responds both to internal and external challenges [78]. Several mechanisms may be involved here, including intestinal barrier regulation, immune modulation, enteroendocrine system influence, mediators from the microbiome entering the body, and modulation of the vagus nerve. Therefore, approaches that promote the growth of “beneficial” bacteria could be favorable in conferring resilience against mood disorders. There were, however, differences between strains of probiotic, the dose, and the duration of treatment in the analyzed studies, and further research studies are needed to determine the optimal treatment regime. Nonetheless, this review claims for a consideration of administration of prebiotics and probiotics for the treatment of patients with mood disorders, such as anxiety, depression, and cognitive impairment, particularly those that are able to modulate the ECS in a beneficial manner. In addition to prebiotics and probiotics, endocannabinoid-like compounds, such as PEA and OEA, or compounds that increase the levels of endocannabinoids (i.e., through metabolic enzyme inhibitors), may be considered for patients with mood and GI disorders, and because of their ability to modulate neuroinflammation as well as microbiota composition, they may also be useful supplements that support both gut and brain health at the same time [56, 60, 71, 75]. In particular, the use of cannabis-derived compounds that decrease the impact of stress, regulate circadian rhythm, and improve mood may represent a winning strategy in case of functional GI diseases. Co-morbidities between mood and GI health might benefit from treatments with prebiotics or probiotics and/or with compounds that modify the ECS tone to a more substantial degree. Overall, neuro-gastro-cannabinology represents a new clinical and research paradigm that focuses on the complex interactions between the CNS, the gut, and the ECS and investigates novel treatments for GI and mood disorders.
Conflict of Interest Statement
The authors have no conflicts of interest to declare.
Funding Sources
No funding was received.
Funding Statement
No funding was received.
References
Untitled section
References
- 1. Davies KJA. Adaptive homeostasis. Mol Aspects Med. 2016;49:1–7. 10.1016/J.MAM.2016.04.007.
- 2. Sayegh AI, Washington MC. Back to basics: regulation of the gastrointestinal functions. J Gastrointest Dig Syst. 2012;2(5):1–4. 10.4172/2161-069X.1000118.
- 3. Cryan JF, O’riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The microbiota-gut-brain Axis. Physiol Rev. 2019;99(4):1877–2013. 10.1152/PHYSREV.00018.2018.
- 4. Dipatrizio NV. Endocannabinoids in the gut. Cannabis Cannabinoid Res. 2016;1(1):67–77. 10.1089/CAN.2016.0001.
- 5. Lee Y, Jo J, Chung HY, Pothoulakis C, Im E. Endocannabinoids in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2016;311(4):G655–G666. 10.1152/AJPGI.00294.2015.
- 6. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462. 10.1124/PR.58.3.2.
- 7. Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front Behav Neurosci. 2012;6:9. 10.3389/fnbeh.2012.00009.
- 8. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771–84. 10.1038/nrd1495.
- 9. Rodríguez de Fonseca F, del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40(1):2–14. 10.1093/ALCALC/AGH110.
- 10. Watkins BA, Kim J. The endocannabinoid system: directing eating behavior and macronutrient metabolism. Front Psychol. 2014;5:1506. 10.3389/fpsyg.2014.01506.
- 11. Kilaru A, Chapman KD. The endocannabinoid system. Essays Biochem. 2020;64(3):485–99. 10.1042/EBC20190086.
- 12. Uranga JA, Vera G, Abalo R. Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018 Nov;157:134–47. 10.1016/j.bcp.2018.07.048.
- 13. Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, Srivastava PK. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc Natl Acad Sci U S A. 2017;114:5005–10.
- 14. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8(5):585–9. 10.1038/NN1457.
- 15. Soria-Gómez E, Bellocchio L, Reguero L, Lepousez G, Martin C, Bendahmane M, et al. The endocannabinoid system controls food intake via olfactory processes. Nat Neurosci. 2014;17(3):407–15. 10.1038/NN.3647.
- 16. Berland C, Castel J, Terrasi R, Montalban E, Foppen E, Martin C, et al. Identification of an endocannabinoid gut-brain vagal mechanism controlling food reward and energy homeostasis. Mol Psychiatry. 2021;27(4):2340–54. 10.1038/s41380-021-01428-z.
- 17. Wilson NL, Peterson SN, Ellis RJ. Cannabis and the gut-brain Axis communication in HIV infection. Cannabis Cannabinoid Res. 2021;6(2):92–104.
- 18. Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain–gut Axis. Gastroenterology. 2016;151(2):252–66. 10.1053/J.GASTRO.2016.04.015.
- 19. Storr MA, Sharkey KA. The endocannabinoid system and gut–brain signalling. Curr Opin Pharmacol. 2007;7(6):575–82. 10.1016/J.COPH.2007.08.008.
- 20. Bisogno T, Lauritano A, Piscitelli F. The endocannabinoid system: a bridge between alzheimer’s disease and gut microbiota. Life. 2021;11(9):934. 10.3390/LIFE11090934.
- 21. Butler MI, Cryan JF, Dinan TG. Man and the microbiome: a new theory of everything? 2019;15(2):371–98. 10.1146/annurev-clinpsy-050718-095432.
- 22. Iannotti FA, Di Marzo V. The gut microbiome, endocannabinoids and metabolic disorders. J Endocrinol. 2021;248(2):R83–R97. 10.1530/JOE-20-0444.
- 23. Anonymous . Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain – PMC. n.d. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770330/ (accessed January 12, 2023).
- 24. Akirav I. Cannabinoids modulation of emotional and non-emotional memory processes after stress. Cannabinoid Modul Emot Mem Motiv. 2015:23–43. 10.1007/978-1-4939-2294-9_2.
- 25. Campolongo P, Fattore L. Cannabinoid modulation of emotion, memory, and motivation. Cannabinoid Modul Emot Mem Motiv. 2015:1–467. 10.1007/978-1-4939-2294-9.
- 26. Lichtman AH, Varvel SA, Martin BR. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fat Acids. 2002;66(2–3):269–85. 10.1054/PLEF.2001.0351.
- 27. Balsevich G, Petrie GN, Hill MN. Endocannabinoids: effectors of glucocorticoid signaling. Front Neuroendocrinol. 2017;47:86–108. 10.1016/J.YFRNE.2017.07.005.
- 28. Hillard CJ. Stress regulates endocannabinoid-CB1 receptor signaling. Semin Immunol. 2014;26(5):380–8. 10.1016/J.SMIM.2014.04.001.
- 29. Micale V, Drago F. Endocannabinoid system, stress and HPA axis. Eur J Pharmacol. 2018;834:230–9. 10.1016/J.EJPHAR.2018.07.039.
- 30. Hill MN, Gorzalka BB. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets. 2009;8(6):451–8. 10.2174/187152709789824624.
- 31. Lowe H, Toyang N, Steele B, Bryant, J, Ngwa, W. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):9472. 10.3390/IJMS22179472.
- 32. Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016;1:154–65.
- 33. Walker WH, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and mental health. Transl Psychiatry. 2020 101 2020;10(1):28–13. 10.1038/s41398-020-0694-0.
- 34. Duboc H, Coffin B, Siproudhis L. Disruption of circadian rhythms and gut motility: an overview of underlying mechanisms and associated pathologies. J Clin Gastroenterol. 2020;54(5):405–14. 10.1097/MCG.0000000000001333.
- 35. Kesner AJ, Lovinger DM. Cannabinoids, endocannabinoids and sleep. Front Mol Neurosci. 2020;13:125. 10.3389/fnmol.2020.00125.
- 36. Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med. 2011;17(10):1228–30. 10.1038/NM.2435.
- 37. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut. 2001;48(6):859–67. 10.1136/gut.48.6.859.
- 38. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126(1):21–38. 10.1016/J.PHARMTHERA.2009.12.005.
- 39. Alger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci. 2011;34(6):304–15. 10.1016/J.TINS.2011.03.003.
- 40. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153(2):263–70. 10.1038/SJ.BJP.0707486.
- 41. Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016;151(2):252–66. 10.1053/J.GASTRO.2016.04.015.
- 42. Jones MP, Tack J, Van Oudenhove L, Walker MM, Holtmann G, Koloski NA, et al. Mood and anxiety disorders precede development of functional gastrointestinal disorders in patients but not in the population. Clin Gastroenterol Hepatol. 2017;15(7):1014–20.e4. 10.1016/J.CGH.2016.12.032.
- 43. Shah E, Rezaie A, Riddle M, Pimentel M. Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence? Ann Gastroenterol. 2014;27(3):224–30.
- 44. De la Roca-Chiapas JM, Solís-Ortiz S, Fajardo-Araujo M, Sosa M, Córdova-Fraga T, Rosa-Zarate A. Stress profile, coping style, anxiety, depression, and gastric emptying as predictors of functional dyspepsia: a case-control study. J Psychosom Res. 2010;68(1):73–81. 10.1016/J.JPSYCHORES.2009.05.013.
- 45. Lee YB, Yu J, Choi HH, Jeon BS, Kim HK, Kim SW, et al. The association between peptic ulcer diseases and mental health problems: a population-based study: a STROBE compliant article. Medicine. 2017 Aug;96(34):e7828. 10.1097/MD.0000000000007828.
- 46. Ruiz de Azua I, Lutz B. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues. Cell Mol Life Sci. 2019;76(7):1341–63. 10.1007/S00018-018-2994-6.
- 47. Srivastava RK, Lutz B, Ruiz de Azua I. The microbiome and gut endocannabinoid system in the regulation of stress responses and metabolism. Front Cell Neurosci. 2022;16:156. 10.3389/fncel.2022.867267.
- 48. Guida F, Turco F, Iannotta M, De Gregorio D, Palumbo I, Sarnelli G, et al. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav Immun. 2018;67:230–45. 10.1016/J.BBI.2017.09.001.
- 49. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066–71. 10.1073/PNAS.1219451110.
- 50. Mehrpouya-Bahrami P, Chitrala KN, Ganewatta MS, Tang C, Murphy EA, Enos RT, et al. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci Rep. 2017;7(1):15645. 10.1038/S41598-017-15154-6.
- 51. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191. 10.3402/MEHD.V26.26191.
- 52. Schiano Moriello A, Di Marzo V, Petrosino S. Mutual links between the endocannabinoidome and the gut microbiome, with special reference to companion animals: a nutritional viewpoint. Animals. 2022;12(3):348. 10.3390/ANI12030348.
- 53. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37(1):47–55. 10.1007/S00281-014-0454-4.
- 54. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009;136(6):2003–14. 10.1053/J.GASTRO.2009.01.075.
- 55. Mitrea L, Nemeş SA, Szabo K, Teleky BE, Vodnar DC. Guts imbalance imbalances the brain: a review of gut microbiota association with neurological and psychiatric disorders. Front Med. 2022;9:813204. 10.3389/fmed.2022.813204.
- 56. Guida F, Boccella S, Belardo C, Iannotta M, Piscitelli F, De Filippis F, et al. Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain. Brain Behav Immun. 2020;85:128–41. 10.1016/j.bbi.2019.04.006.
- 57. Chevalier G, Siopi E, Guenin-Macé L, Pascal M, Laval T, Rifflet A, et al. Effect of gut microbiota on depressive-like behaviors in mice is mediated by the endocannabinoid system. Nat Commun. 2020;11(1):6363. 10.1038/S41467-020-19931-2.
- 58. Manca C, Boubertakh B, Leblanc N, Deschênes T, Lacroix S, Martin C, et al. Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. J Lipid Res. 2020;61(1):70–85. 10.1194/JLR.RA119000424.
- 59. Minichino A, Jackson MA, Francesconi M, Steves CJ, Menni C, Burnet PWJ, et al. Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort. Mol Psychiatry. 2021;26(11):6269–76. 10.1038/S41380-021-01147-5.
- 60. Mansur RB, Zugman A, Ahmed J, Cha DS, Subramaniapillai M, Lee Y, et al. Treatment with a GLP−1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur Neuropsychopharmacol. 2017;27(11):1153–62. 10.1016/J.EURONEURO.2017.08.433.
- 61. Chen Z, Guo L, Zhang Y, Walzem RL, Pendergast JS, Printz RL, et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest. 2014;124(8):3391–406. 10.1172/JCI72517.
- 62. De Weerth C. Do bacteria shape our development? Crosstalk between intestinal microbiota and HPA axis. Neurosci Biobehav Rev. 2017;83:458–71. 10.1016/j.neubiorev.2017.09.016.
- 63. Sudo N. Microbiome, HPA axis and production of endocrine hormones in the gut. Adv Exp Med Biol. 2014;817:177–94. 10.1007/978-1-4939-0897-4_8.
- 64. Marcus DJ, Bedse G, Gaulden AD, Ryan JD, Kondev V, Winters ND, et al. Endocannabinoid signaling collapse mediates stress-induced amygdalo-cortical strengthening. Neuron. 2020;105(6):1062–76.e6. 10.1016/J.NEURON.2019.12.024.
- 65. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108(38):16050–5. 10.1073/PNAS.1102999108.
- 66. Burokas A, Arboleya S, Moloney RD, Peterson VL, Murphy K, Clarke G, et al. Targeting the microbiota-gut-brain Axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol Psychiatry. 2017;82(7):472–87. 10.1016/J.BIOPSYCH.2016.12.031.
- 67. Slyepchenko A, Carvalho AF, Cha DS, Kasper S, McIntyre RS. Gut emotions – mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. CNS Neurol Disord Drug Targets. 2014;13(10):1770–86.
- 68. Noonan S, Zaveri M, Macaninch E, Martyn K. Food & mood: a review of supplementary prebiotic and probiotic interventions in the treatment of anxiety and depression in adults. BMJ Nutr Prev Heal. 2020;3(2):351–62. 10.1136/BMJNPH-2019-000053.
- 69. Chao L, Liu C, Sutthawongwadee S, Li Y, Lv W, Chen W, et al. Effects of probiotics on depressive or anxiety variables in healthy participants under stress conditions or with a depressive or anxiety diagnosis: a meta-analysis of randomized controlled trials. Front Neurol. 2020;11:421. 10.3389/fneur.2020.00421.
- 70. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011;2(4):256–61.
- 71. Brugnatelli V, Turco F, Freo U, Zanette G. Irritable bowel syndrome: manipulating the endocannabinoid system as first-line treatment. Front Neurosci. 2020;14:371. 10.3389/FNINS.2020.00371.
- 72. Cluny NL, Keenan CM, Reimer RA, Le Foll B, Sharkey KA. Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with δ9-tetrahydrocannabinol. PLoS One. 2015;10(12):e0144270. 10.1371/JOURNAL.PONE.0144270.
- 73. Kang C, Wang B, Kaliannan K, Wang X, Lang H, Hui S, et al. Gut microbiota mediates the protective effects of dietary capsaicin against chronic low-grade inflammation and associated obesity induced by high-fat diet. mBio. 2017;8(3):e00470–17. 10.1128/MBIO.00470-17.
- 74. Skinner CM, Nookaew I, Ewing LE, Wongsurawat T, Jenjaroenpun P, Quick CM, et al. Potential probiotic or trigger of gut inflammation – the janus-faced nature of cannabidiol-rich cannabis extract. J Diet Suppl. 2020;17(5):543–60. 10.1080/19390211.2020.1761506.
- 75. Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, depression, and the microbiome: a role for gut peptides. Neurother. 2018;15(1):36–59. 10.1007/S13311-017-0585-0.
- 76. Rao TSS, Asha MR, Ramesh BN, Rao KSJ. Understanding nutrition, depression and mental illnesses. Indian J Psychiatry. 2008;50(2):77–82. 10.4103/0019-5545.42391.
- 77. Aguilera Vasquez N, Nielsen DE. The endocannabinoid system and eating behaviours: a review of the current state of the evidence. Curr Nutr Rep. 2022;11(4):665–74. 10.1007/s13668-022-00436-x.
- 78. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res. 2009;60(2):77–84. 10.1016/J.PHRS.2009.02.010.